Oncology Clinical Trials in New York, NY
As of July 2026, 803 paid clinical trials are recruiting for Oncology in New York, New York. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in New York
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
A Study of a New PET Scanner in People With Cancer
A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer
A Study of CRD3874-SI in People With Leukemia
A Study of a Side Effects and Resource Navigation Program for People With Cancer
A Study of a Urine Test to Detect Colorectal Cancer
809 clinical trials for Oncology
·Clear filters·↓ Download CSVA Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
About research studies in New York
New York has approximately 3,340 recruiting research studies across a wide range of therapeutic areas. New York is home to leading academic medical centers such as Memorial Sloan Kettering, Weill Cornell Medicine, Mount Sinai, NYU Langone, and Columbia University Irving Medical Center. These institutions anchor a research ecosystem that covers oncology, cardiology, neurology, and rare disease.
Top Research Study Locations in New York
Researchers run research studies in New York, NY at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Memorial Sloan Kettering Cancer Center | Breast Cancer, Prostate Cancer, Endometrial Cancer | 460 |
| NYU Langone Health | Prostate Cancer, Lung Cancer, Cardiovascular Diseases | 304 |
| Icahn School of Medicine at Mount Sinai | Myelofibrosis, Prostate Cancer, Advanced Solid Tumor | 257 |
| Columbia University Irving Medical Center | Obesity, Insulin Resistance, Hyperinsulinemia | 179 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activities) | Breast Cancer, Multiple Myeloma, Lung Cancer | 157 |
| Weill Cornell Medicine | Depression, Heart Failure, Prostate Cancer | 134 |
| Mount Sinai Hospital | Heart Failure, Acute Myeloid Leukemia, Anatomic Stage IV Breast Cancer AJCC v8 | 121 |
| Columbia University Medical Center | Breast Cancer, Coronary Artery Disease, Obesity | 119 |
| Columbia University | Amyotrophic Lateral Sclerosis, Obstetrical Complications, Alzheimer Disease | 105 |
| Hospital for Special Surgery | Systemic Lupus Erythematosus, Opioid Use, Rheumatoid Arthritis | 66 |
| Laura and Isaac Perlmutter Cancer Center at NYU Langone | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Solid Neoplasm, Anatomic Stage II Breast Cancer AJCC v8 | 58 |
| Lenox Hill Hospital | Atrial Fibrillation, Anatomic Stage II Breast Cancer AJCC v8, Head and Neck Squamous Cell Carcinoma | 49 |
| NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Acute Myeloid Leukemia | 48 |
| Mount Sinai | Ovarian Cancer, AML, Advanced Solid Tumors | 46 |
| Weill Cornell Medical College | ARDS, ARDS (Acute Respiratory Distress Syndrome), Acute Respiratory Distress Syndrome | 46 |
| Mount Sinai West | Breast Cancer, Intracerebral Hemorrhage, Anatomic Stage II Breast Cancer AJCC v8 | 42 |
| Memorial Sloan Kettering Cancer Center (All Protocol Activites) | Breast Cancer, Prostate Cancer, Pancreatic Cancer | 39 |
| NYP/Weill Cornell Medical Center | B Acute Lymphoblastic Leukemia, Malignant Solid Neoplasm, Anatomic Stage IV Breast Cancer AJCC v8 | 32 |
| New York University | Inflammatory Bowel Disease (IBD), Acute or Chronic Coronary Artery Disease, Adenine Phosphoribosyltransferase Deficiency | 30 |
| Memorial Sloan-Kettering Cancer Center | Advanced Solid Tumor, Advanced Solid Tumors, Breast Cancer | 24 |
| Manhattan Eye Ear and Throat Hospital | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8 | 21 |
| NYU Langone | Acute Gastrointestinal Bleeding, Advanced Breast Cancer, Advanced Cancer | 20 |
| Montefiore Medical Center | Mitral Regurgitation, Coronary Artery Disease, AML, Adult | 19 |
| Mount Sinai Chelsea | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Ovarian Carcinoma | 19 |
| NYU Langone Medical Center | Mesothelioma, NSCLC, Non Small Cell Lung Cancer | 18 |
Active & Upcoming Studies in New York (2026)
Recruiting trials in New York grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (1,127 active studies)
- Improving Affordability in Cancer Care Through Economic Screening and Support (I-ACCESS) · UNC Lineberger Comprehensive Cancer Center
- Signatera Assessment in Early-Stage Endometrial Cancer · Natera, Inc.
Neurology & pain (199 active studies)
- Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau · Phase 1 · Columbia University
- Optimal Dosing of High-Intensity Locomotor Training for Step Attainment and Locomotor Outcomes in Stroke Patients Undergoing Acute Inpatient Rehabilitation · NYU Langone Health
Cardiovascular (190 active studies)
Diabetes & metabolic (106 active studies)
- South Asians With Type 2 Diabetes at Risk for Depression · NYU Langone Health
- Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · Columbia University
Mental health & behavior (105 active studies)
- Whole-Body Hyperthermia for Mood and Anxiety Disorders · Weill Medical College of Cornell University
- Permanent Supportive Housing Overdose Prevention+ Study · NYU Langone Health
HIV / STI (49 active studies)
Pediatric (31 active studies)
- Neonatal Neurological Observation With Video AI · Artemis AI Labs
- Bilevel Positive Airway Pressure (BPAP) for Severe Asthma · Columbia University
Vaccines (21 active studies)
- SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction · Phase 2 · Icahn School of Medicine at Mount Sinai
- Harnessing Optimism and Perseverance in the Face of Long COVID-Español · Icahn School of Medicine at Mount Sinai
Eye & vision (16 active studies)
- Know Your Pressures NYC · Columbia University
- A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration · Phase 2 · Novartis Pharmaceuticals
Common conditions studied in New York
- Breast Cancer (89 active studies). Breast cancer trials evaluate new hormone therapies, targeted drugs, and immunotherapy combinations aimed at improving survival and reducing recurrence.
- Prostate Cancer (69 active studies). Prostate cancer studies test next-generation hormone therapies, PARP inhibitors, and radioligand treatments for both localized and advanced disease.
- Multiple Myeloma (47 active studies). Recruiting Multiple Myeloma studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
- Colorectal Cancer (39 active studies). Colorectal cancer trials explore novel chemotherapy combinations, targeted agents, and immunotherapy for microsatellite-instability-high tumors.
- Ovarian Cancer (39 active studies). Ovarian cancer research examines PARP inhibitors, maintenance therapies, and antibody-drug conjugates for recurrent and platinum-resistant disease.
- Endometrial Cancer (36 active studies). Recruiting Endometrial Cancer studies evaluate investigational treatments, diagnostics, and supportive care approaches to improve patient outcomes.
Leading research sponsors in New York
- Memorial Sloan Kettering Cancer Center
- NYU Langone Health
- Columbia University
- Icahn School of Medicine at Mount Sinai
- Weill Medical College of Cornell University
Local regulations and guidelines
Clinical trials in New York are governed by U.S. Food and Drug Administration (FDA) regulations, Office for Human Research Protections (OHRP) standards, and federal HIPAA privacy rules. Every study is reviewed by an Institutional Review Board (IRB) to protect participant safety and ensure informed consent. Trials conducted in New York must also comply with the NY SHIELD Act's data-protection requirements and additional oversight from the New York State Department of Health.
Compensation & what to expect
- How payment typically works
- Compensation is most often provided through reloadable electronic study cards or direct deposit, paid out per completed visit rather than as a lump sum. Amounts vary by the time required, the number of visits, and the study's complexity — overnight stays and inpatient pharmacology studies generally pay more than short outpatient surveys. The exact amount is disclosed in writing during informed consent before any visit.
- Healthy volunteers
- Healthy participants aged 18 and older can earn compensation by joining vaccine, pharmacology, and biomarker studies in New York. These trials check how a new drug or vaccine behaves in healthy bodies before later-phase testing. Many sites maintain a healthy-volunteer registry so you hear about new opportunities first.
- What's included beyond payment
- Most trials cover study-related medical care at no cost — physical exams, lab work, imaging, the investigational treatment itself, and follow-up visits with the research team. Insurance is not required to participate. Free check-ups and access to specialists are common reasons participants return for additional studies.
- Travel and time
- Many sponsors reimburse travel, parking, mileage, and lost wages for visit days. Long-running studies and trials that require frequent visits often raise stipends accordingly. Ask the study coordinator for the visit schedule and reimbursement policy before you commit.
- Asking about compensation
- Compensation is set per protocol and per site, so figures are not published in trial registries. The fastest way to confirm payment for a specific study is to contact the recruiting site listed on the study record. Coordinators are accustomed to this question and will quote the per-visit and total amounts up front.
How to find a clinical trial in New York
Hipa.ai aggregates every recruiting study in New York from ClinicalTrials.gov and refreshes the list daily. Use the filters above to narrow by condition, facility, age, phase, or healthy-volunteer eligibility, then click any study title to view full details — eligibility criteria, intervention, location, and sponsor contact information. To enroll, reach out to the central study contact listed on the study detail page; the research coordinator will walk you through the screening process.
Frequently asked questions
How many paid clinical trials are currently recruiting in New York?
There are approximately 3,340 recruiting clinical trials in New York, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New York pay participants?
Most recruiting trials in New York compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New York?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New York?
The most common conditions under active study in New York include Breast Cancer (89), Prostate Cancer (69), Multiple Myeloma (47), Colorectal Cancer (39), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New York?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New York on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New York?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New York?
Recruiting research sites in New York include Memorial Sloan Kettering Cancer Center, NYU Langone Health, Icahn School of Medicine at Mount Sinai, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New York right now?
The largest active categories in New York are Cancer & tumors (1,127), Neurology & pain (199), Cardiovascular (190). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.